Noxopharm Ltd. has released a press release.
$7.9 Million Fully Underwritten Entitlement Offer Announced
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Noxopharm March 2020 Quarterly Report & Appendix 4C
- Abscopal Responses Achieved in Prostate Cancer
- Pipeline Expands With Potential New Brain Cancer Treatment
- Approval to be sought for COVID-19 Clinical Study in U.S.
- Noxopharm Investigating Potential COVID-19 Treatment
Later from Noxopharm
- Entitlement Offer Prospectus
- FDA allows Veyonda Pre-IND Submission for COVID-19
- ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
- Pro-rata Non-Renounceable Rights Issue Fully Allocated
- COVID-19 Trial Program to Commence in Europe
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm